| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.29 | 9e-15 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.29 | 2e-14 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.22 | 2e-10 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.21 | 2e-10 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-09 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.24 | 4e-09 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | 0.2 | 5e-09 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.22 | 7e-09 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-08 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-08 |